Incyte’s Povorcitinib Shows Sustained Efficacy in Phase 3 HS Trial, Supports 2025/2026 Regulatory Submissions

Incyte Corporation (NASDAQ:INCY) is one of the best innovative stocks to buy now. On September 17, Incyte announced new 24-week interim data from its pivotal Phase 3 STOP-HS clinical trial program for povorcitinib/INCB54707, which is an oral small-molecule, highly-selective JAK1 inhibitor, in adult patients with moderate to severe hidradenitis suppurativa/HS.

The results support the company’s planned regulatory submissions for povorcitinib in HS, expected in Europe in 2025 and the US in early 2026. Both Phase 3 studies, STOP-HS1 and STOP-HS2, previously met their primary endpoint at the 12-week mark for both tested doses (45 mg and 75 mg) administered once daily, which was the achievement of HiSCR50.

The new 24-week data show continued clinically meaningful and statistically significant improvements, with nearly 60% of efficacy-evaluable patients across both povorcitinib treatment groups in both studies achieving HiSCR50. The overall safety profile was consistent with previous data, and both doses were well tolerated. HS is a chronic inflammatory condition estimated to affect more than 150,000 patients with moderate to severe HS in the US.

Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics in the US, Europe, Canada, and Japan.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.